Next Article in Journal
Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
Previous Article in Journal
Complementary Medicine: Risks to Infants and Children
Open AccessArticle

Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers

1
Merck & Co., Inc., Kenilworth, NJ 07033, USA
2
Minassian Biostatistics, Inc., San Diego, CA 92121, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(6), 150; https://doi.org/10.3390/jcm7060150
Received: 6 June 2018 / Accepted: 13 June 2018 / Published: 14 June 2018
(This article belongs to the Section Pharmacology)
Therapeutic doses of tedizolid phosphate, an oxazolidinone antibiotic, lack monoamine oxidase inhibition in vivo, potentially resulting in an improved safety profile versus other oxazolidinones. This randomized, double-blind, placebo-controlled, 2-period, 2-sequence, crossover, phase 1 study (NCT01577459) assessed the potential for pharmacokinetic (PK) interactions between tedizolid and pseudoephedrine. Eighteen healthy volunteers (age: 18–45 years) were block-randomized to 1 of 2 treatment sequences containing 2 treatment periods (tedizolid phosphate or placebo once daily for 4 days; single dose of pseudoephedrine 60 mg on day 5) separated by a 2-day washout. Median time to maximum plasma concentration for tedizolid and pseudoephedrine ranged from 3 to 4 h, regardless of treatment coadministration. Steady-state tedizolid had no effect on the PK of pseudoephedrine; geometric mean ratio and 90% confidence interval remained within the no-effect 0.8 to 1.25 boundaries. The maximum observed concentration of tedizolid decreased by approximately 14% when pseudoephedrine was coadministered; no changes in the area under the plasma concentration-time curve or the minimum observed plasma concentration occurred. All adverse events (AEs) were mild, and there were no serious AEs or study drug discontinuations. No meaningful PK interactions occurred between tedizolid and pseudoephedrine, and tedizolid was well tolerated when administered in conjunction with pseudoephedrine. View Full-Text
Keywords: antibiotics; drug interactions; oxazolidinone; infectious disease; acute bacterial skin infections; pharmacokinetics antibiotics; drug interactions; oxazolidinone; infectious disease; acute bacterial skin infections; pharmacokinetics
Show Figures

Figure 1

MDPI and ACS Style

Flanagan, S.; Minassian, S.L.; Prokocimer, P. Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers. J. Clin. Med. 2018, 7, 150.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop